Meeting
2017 ASCO Annual Meeting
Trabectedin for advanced soft tissue sarcoma: Ten-year real-life perspective.
Authors
Sivan Shamai
Tel Aviv Medical Center and Sackler School of Medicine, Tel Aviv, Israel
Sivan Shamai , Ofer Merimsky
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Citation
J Clin Oncol 35, 2017 (suppl; abstr 11060)
DOI
10.1200/JCO.2017.35.15_suppl.11060
Abstract #
11060
Poster Bd #
383
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Five-year results of a phase 2 trial using ipilimumab (I), nivolumab (N), and trabectedin (T) for previously untreated advanced soft tissue sarcoma (NCT03138161).
First Author: Erlinda Maria Gordon
Poster
2014 ASCO Annual Meeting
Predictive value of BRCA1 haplotype for trabectedin efficacy in patients with advanced soft-tissue sarcoma.
First Author: Audrey Laroche
Poster
2023 ASCO Annual Meeting
A phase II trial with safety lead-in to evaluate the addition of sotigalimab, a CD40 agonistic monoclonal antibody, to standard-of-care doxorubicin for the treatment of advanced sarcoma.
First Author: Sminu (Sam) Bose
Poster
2022 ASCO Annual Meeting
Trabectedin in advanced retroperitoneal well differentiated/dedifferentiated liposarcoma and leiomyosarcoma (TRAVELL): Results of a phase 2 study from Italian sarcoma group (ISG).
First Author: Roberta Sanfilippo